8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report (Oct 31, 2000)

Filed October 31, 2000For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) filed an 8-K on October 31, 2000, to report the finalization of the purchase price adjustment related to its August 16, 1999, acquisition of SmithKline Beecham's clinical laboratory business (SBCL). The adjustment resulted in a net payment of $95.0 million from SmithKline Beecham to Quest Diagnostics, which will be recorded as a reduction in the purchase price in the fourth quarter of 2000. This filing also includes restated financial statements for SBCL and updated pro forma combined financial information for Quest Diagnostics to reflect these changes. Importantly, the company emphasizes that these adjustments, including the purchase price reduction and the completion of purchase price allocation, have no impact on Quest Diagnostics' previously reported historical financial statements. The filing primarily serves to update pro forma disclosures and incorporate the final financial impact of the SBCL acquisition agreement, providing a more refined view of the combined entity's financial picture as of the reporting date.

Key Highlights

  • 1Finalized purchase price adjustment for the SmithKline Beecham Clinical Laboratories (SBCL) acquisition, resulting in a $95.0 million net payment to Quest Diagnostics.
  • 2The $95.0 million payment will be recorded as a reduction in the acquisition's purchase price in Q4 2000.
  • 3SBCL's historical financial statements (for periods ending December 31, 1998, 1997, 1996 and interim periods in 1999) have been restated.
  • 4Quest Diagnostics is amending and updating its previously filed pro forma combined financial information to reflect the finalized purchase price adjustment and allocation.
  • 5The company explicitly states that these adjustments do not impact its previously reported historical financial statements, either pre- or post-acquisition.
  • 6Termination of the Category Three Laboratory Data Access Agreement and related Participation Agreement with SmithKline Beecham, while the Category One agreement remains in effect.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the finalization of the purchase price adjustment for the acquisition of SmithKline Beecham's clinical laboratory business (SBCL). This adjustment resulted in a net payment of $95.0 million to Quest Diagnostics, and the filing also updates the company's pro forma financial information to reflect this and other related accounting completions.

The $95.0 million net payment from SmithKline Beecham will be recorded in Quest Diagnostics' historical financial statements in the fourth quarter of 2000 as a reduction of the purchase price for the SBCL acquisition. The filing explicitly states that this, along with purchase price allocation adjustments, will not impact previously reported historical financial statements.

Yes, SmithKline Beecham restated certain historical financial statements of SBCL as of and for periods ending December 31, 1998, 1997, 1996, and interim periods in 1999. These restated statements are included as exhibits in this 8-K filing.

Yes, this filing revises and updates previously reported pro forma combined financial information. This is to reflect the finalized SBCL purchase price adjustment, the completion of the purchase price allocation, and other revised adjustments that were previously included.